UK markets close in 4 hours 13 minutes
  • FTSE 100

    6,620.82
    +32.29 (+0.49%)
     
  • FTSE 250

    21,227.53
    +6.07 (+0.03%)
     
  • AIM

    1,190.25
    -1.92 (-0.16%)
     
  • GBP/EUR

    1.1566
    +0.0013 (+0.11%)
     
  • GBP/USD

    1.3915
    -0.0006 (-0.04%)
     
  • BTC-GBP

    35,075.74
    +600.45 (+1.74%)
     
  • CMC Crypto 200

    982.75
    -3.90 (-0.40%)
     
  • S&P 500

    3,901.82
    +90.67 (+2.38%)
     
  • DOW

    31,535.51
    +603.14 (+1.95%)
     
  • CRUDE OIL

    60.74
    +0.10 (+0.16%)
     
  • GOLD FUTURES

    1,725.20
    +2.20 (+0.13%)
     
  • NIKKEI 225

    29,408.17
    -255.33 (-0.86%)
     
  • HANG SENG

    29,095.86
    -356.71 (-1.21%)
     
  • DAX

    14,083.58
    +70.76 (+0.50%)
     
  • CAC 40

    5,821.90
    +29.11 (+0.50%)
     

Insights on the IV and Oral Iron Drugs Global Market to 2026 - by Route of Administration, Application, Patient Group, Distribution and Geography

Research and Markets
·9-min read

Dublin, Feb. 19, 2021 (GLOBE NEWSWIRE) -- The "IV and Oral Iron Drugs Market - Global Outlook and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report

The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021-2026.

The global IV and oral iron drugs market is expected to grow due to the prevalence of iron deficiency (ID). This deficiency is a highly widespread nutritional disorder, affecting around one-fourth of the global population, especially women and children. It is one of the predominant causes of anemia. Anemia accounts for around 9% of the total global disease burden. Several chronic diseases are frequently associated with iron deficiency anemia (IDA) such as chronic kidney disease (CKD), chronic heart failure, cancer, and inflammatory bowel diseases. As anemia is associated with chronic fatigue, diminished well-being, and impaired cognitive function, the treatment with oral and IV iron drugs reduces the need for blood transfusion in patients. Further, the WHO rates ID as the most common and widespread nutritional disorder globally, and its prevalence is expected to grow with the aging population and the incidence of various chronic disorders.

The following factors are likely to contribute to the growth of the IV and Oral Iron Drugs market during the forecast period:

  • Strategic Collaborations & Licensing Opportunities

  • Investigational Iron Drugs

  • Increasing Availability of Branded Iron Therapeutics and Expanded Indication Approvals

The study considers the present scenario of the IV and Iron drugs market and its market dynamics for the period 2020-2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market.

KEY QUESTIONS ANSWERED
1. What is the IV and oral iron drugs market size and growth rate during the forecast period?
2. What is the impact of COVID-19 on the intravenous iron drugs market share?
3. Which regions are expected to observe high revenues for IV and oral drugs during the forecast period?
4. Who are the notable market players in the global IV and oral iron drugs market?
5. What are the opportunities and threats faced by key vendors in the market?

Key Topics Covered:

1 Research Methodology

2 Research Objectives

3 Research Process

4 Scope & Coverage
4.1 Market Definition
4.1.1 Inclusions
4.1.2 Exclusions
4.2 Base Year
4.3 Scope of The Study
4.4 Market Segments
4.4.1 Market Segmentation by Route of Administration (ROA)
4.4.2 Market Segmentation by Application
4.4.3 Market Segmentation by Patient Group
4.4.4 Market Segmentation by Distribution
4.4.5 Market Segmentation by Geography

5 Report Assumptions & Caveats
5.1 Key Caveats
5.2 Currency Conversion
5.3 Market Derivation

6 Market at a Glance

7 Introduction
7.1 Iron Deficiency: An Overview
7.1.1 Background
7.1.2 Symptoms of ID
7.1.3 Different Causes of ID
7.1.4 Iron Drugs for the Treatment of ID

8 Market Opportunities & Trends
8.1 Strategic Collaborations & Licensing Opportunities
8.2 Investigational Iron Drugs
8.3 Increasing Availability Of Branded Iron Therapeutics And Expanded Indication Approvals

9 Market Growth Enablers
9.1 Rising Incidence/Prevalence Of Iron Deficiency
9.2 High Demand For Dextran-Free Iv Iron Therapeutics
9.3 Growing Demand For Iron Replacement Therapies Among Kidney Disease Patients

10 Market Restraints
10.1 Presence of Alternative Options For Treating ID and IDA
10.1.1 Natural Food Intake
10.1.2 Combination Dietary Supplements & Nutritional Health Products
10.1.3 Ayurvedic Medicine & TCM
10.2 Adverse Events Associated With Oral & IV Iron Drugs
10.3 Availability of Low-Cost Generic Iron Drugs

11 Market Landscape
11.1 Market Overview
11.1.1 COVID-19 Impact on Global IV & Oral Iron Drugs Market
11.2 Market Size & Forecast
11.3 Five Forces Analysis
11.3.1 Threat of New Entrants
11.3.2 Bargaining Power of Suppliers
11.3.3 Bargaining Power of Buyers
11.3.4 Threat of Substitutes
11.3.5 Competitive Rivalry

12 Route of Administration
12.1 Market Snapshot & Growth Engine
12.2 Market Overview
12.3 IV Iron Drugs
12.3.1 Market Overview
12.3.2 Market Size & Forecast
12.3.3 IV Iron Drugs: Geography Segmentation
12.4 Oral Iron Drugs
12.4.1 Market Overview
12.4.2 Market Size & Forecast
12.4.3 Oral Iron Drugs: Geography Segmentation

13 Application
13.1 Market Snapshot & Growth Engine
13.2 Market Overview
13.3 Nephrology
13.3.1 Market Overview
13.3.2 Market Size & Forecast
13.3.3 Nephrology: Geography Segmentation
13.4 OBGYN
13.4.1 Market Overview
13.4.2 Market Size & Forecast
13.4.3 OBGYN: Geography Segmentation
13.5 Surgery
13.5.1 Market Overview
13.5.2 Market Size & Forecast
13.5.3 Surgery: Geography Segmentation
13.6 Gastroenterology
13.6.1 Market Overview
13.6.2 Market Size & Forecast
13.6.3 Gastroenterology: Geography Segmentation
13.7 Oncology
13.7.1 Market Overview
13.7.2 Market Size & Forecast
13.7.3 Oncology: Geography Segmentation
13.8 Heart Failure
13.8.1 Market Overview
13.8.2 Market Size & Forecast
13.8.3 Heart Failure: Geography Segmentation

14 Patient Group
14.1 Market Snapshot & Growth Engine
14.2 Market Overview
14.3 Adult
14.3.1 Market Overview
14.3.2 Market Size & Forecast
14.3.3 Adult: Geography Segmentation
14.4 Pediatric
14.4.1 Market Overview
14.4.2 Market Size & Forecast
14.4.3 Pediatric: Geography Segmentation

15 Distribution
15.1 Market Snapshot & Growth Engine
15.2 Market Overview
15.3 Hospital Pharmacies
15.3.1 Market Overview
15.3.2 Market Size & Forecast
15.3.3 Hospital Pharmacies: Geography Segmentation
15.4 Offline Retail Pharmacies
15.4.1 Market Overview
15.4.2 Market Size & Forecast
15.4.3 Offline Retail Pharmacies: Geography Segmentation
15.5 Online Channels
15.5.1 Market Overview
15.5.2 Market Size & Forecast
15.5.3 Online Channels: Geography Segmentation

16 Geography
16.1 Market Snapshot & Growth Engine
16.2 Geographic Overview

17 North America
17.1 Market Overview
17.2 Market Size & Forecast
17.3 North America: Route of Administration Segmentation
17.4 North America: Application Segmentation
17.5 North America: Patient Group Segmentation
17.6 North America: Distribution Segmentation
17.7 Key Countries
17.7.1 US: Market Size & Forecast
17.7.2 Canada: Market Size & Forecast

18 Europe
18.1 Market Overview
18.2 Market Size & Forecast
18.3 Europe: Route Of Administration Segmentation
18.4 Europe: Application Segmentation
18.5 Europe: Patient Group Segmentation
18.6 Europe: Distribution Segmentation
18.7 Key Countries
18.7.1 Germany: Market Size & Forecast
18.7.2 UK: Market Size & Forecast
18.7.3 France: Market Size & Forecast
18.7.4 Italy: Market Size & Forecast
18.7.5 Spain: Market Size & Forecast

19 APAC
19.1 Market Overview
19.2 Market Size & Forecast
19.4 APAC: Route of Administration Segmentation
19.5 APAC: Application Segmentation
19.6 APAC: Patient Group Segmentation
19.7 APAC: Distribution Segmentation
19.8 Key Countries
19.8.1 Japan: Market Size & Forecast
19.8.2 China: Market Size & Forecast
19.8.3 Australia: Market Size & Forecast
19.8.4 South Korea: Market Size & Forecast
19.8.5 India: Market Size & Forecast

20 Latin America
20.1 Market Overview
20.2 Market Size & Forecast
20.4 Latin America: Route of Administration Segmentation
20.5 Latin America: Application Segmentation
20.6 Latin America: Patient Group Segmentation
20.7 Latin America: Distribution Segmentation
20.8 Key Countries
20.8.1 Brazil: Market Size & Forecast
20.8.2 Mexico: Market Size & Forecast
20.8.3 Argentina: Market Size & Forecast

21 Middle East & Africa
21.1 Market Overview
21.2 Market Size & Forecast
21.3 Middle East & Africa: Route Of Administration Segmentation
21.4 Middle East & Africa: Application Segmentation
21.5 Middle East & Africa: Patient Group Segmentation
21.6 Middle East & Africa: Distribution Segmentation
21.7 Key Countries
21.7.1 Turkey: Market Size & Forecast
21.7.2 South Africa: Market Size & Forecast
21.7.3 Saudi Arabia: Market Size & Forecast

22 Competitive Landscape
22.1 Competition Overview
22.2 Market Share Analysis
22.2.1 Vifor Pharma
22.2.2 Daiichi Sankyo Company
22.2.3 AMAG Pharmaceuticals
22.2.4 Akebia Therapeutics

23 Key Company Profiles
23.1 Vifor Pharma
23.1.1 Business Overview
23.1.2 Product Offerings
23.1.3 Key Strategies
23.1.4 Key Strengths
23.1.5 Key Opportunities
23.2 Daiichi Sankyo Company
23.2.1 Business Overview
23.2.2 Product Offerings
23.2.3 Key Strategies
23.2.4 Key Strengths
23.2.5 Key Opportunities

24 Other Prominent Vendors
24.1 AMAG Pharmaceuticals
24.1.1 Business Overview
24.1.2 Product Offerings
24.1.3 Key Strategies
24.1.4 Key Strengths
24.1.5 Key Opportunities
24.2 Akebia Therapeutics
24.2.1 Business Overview
24.2.2 Product Offerings
24.2.3 Key Strategies
24.2.4 Key Strengths
24.2.5 Key Opportunities
24.3 Shield Therapeutics
24.3.1 Business Overview
24.3.2 Product Offerings
24.3.3 Key Strategies
24.3.4 Key Strengths
24.3.5 Key Opportunities
24.4 PHARMACOSMOS
24.4.1 Business Overview
24.4.2 Product Offerings
24.4.3 Key Strategies
24.4.4 Key Strengths
24.4.5 Key Opportunities
24.5 Allergan
24.5.1 Business Overview
24.5.2 Product Offerings
24.5.3 Key Strategies
24.5.4 Key Strengths
24.5.5 Key Opportunities
24.6 Sanofi
24.6.1 Business Overview
24.6.2 Product Offerings
24.6.3 Key Strategies
24.6.4 Key Strengths
24.6.5 Key Opportunities
24.7 AOP Orphan Pharmaceuticals
24.7.1 Business Overview
24.7.2 Product Offerings
24.7.3 Key Strategies
24.7.4 Key Strengths
24.7.5 Key Opportunities

25 Other Vendors
25.1 AZAD Pharma
25.1.1 Business Overview
25.1.2 Product Offerings
25.2 Ciron Drugs & Pharmaceuticals
25.2.1 Business Overview
25.2.2 Product Offerings
25.3 Pfizer
25.3.1 Business Overview
25.3.2 Product Offerings
25.4 Rockwell Medical
25.4.1 Business Overview
25.4.2 Product Offerings
25.5 Salveo Lifecare
25.5.1 Business Overview
25.5.2 Product Offerings
25.6 Sunny Pharmaceutical
25.6.1 Business Overview
25.6.2 Product Offerings

26 Report Summary
26.1 Key Takeaways
26.2 Strategic Recommendations

27 Quantitative Summary

28 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/pvkw0c

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900